Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[MED12 mutations were detected in 54% of classical uterine leiomyomas (15/28) and in 15% of cases in myometrium adjacent to leiomyomas (2/13); 34% of leiomyoma/leiomyomatosis in pelvic/retroperitoneal sites (10/29); 0% of extrauterine leiomyomas (0/29); 8% of smooth muscle tumor of uncertain malignant potential (1/12); 30% of uterine leiomyosarcomas (6/20); and 4% of extrauterine leiomyosarcomas (1/25).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP354406.RAn_I_mN6k_5ETy6uAwQocAKsETYRMxffn7Bhhk3dstvo130_assertion description "[MED12 mutations were detected in 54% of classical uterine leiomyomas (15/28) and in 15% of cases in myometrium adjacent to leiomyomas (2/13); 34% of leiomyoma/leiomyomatosis in pelvic/retroperitoneal sites (10/29); 0% of extrauterine leiomyomas (0/29); 8% of smooth muscle tumor of uncertain malignant potential (1/12); 30% of uterine leiomyosarcomas (6/20); and 4% of extrauterine leiomyosarcomas (1/25).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP354406.RAn_I_mN6k_5ETy6uAwQocAKsETYRMxffn7Bhhk3dstvo130_provenance.
• NP375972.RAIs_udl3uX_t4sdkrjv7vlL2OsRYi9_BGBEJRj-E3FWs130_assertion description "[MED12 mutations were detected in 54% of classical uterine leiomyomas (15/28) and in 15% of cases in myometrium adjacent to leiomyomas (2/13); 34% of leiomyoma/leiomyomatosis in pelvic/retroperitoneal sites (10/29); 0% of extrauterine leiomyomas (0/29); 8% of smooth muscle tumor of uncertain malignant potential (1/12); 30% of uterine leiomyosarcomas (6/20); and 4% of extrauterine leiomyosarcomas (1/25).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP375972.RAIs_udl3uX_t4sdkrjv7vlL2OsRYi9_BGBEJRj-E3FWs130_provenance.
• NP781491.RALNO2cf7ERCzMn5I_U4aYdETwsZvLCSrTvelr_n5htdE130_assertion description "[MED12 mutations were detected in 54% of classical uterine leiomyomas (15/28) and in 15% of cases in myometrium adjacent to leiomyomas (2/13); 34% of leiomyoma/leiomyomatosis in pelvic/retroperitoneal sites (10/29); 0% of extrauterine leiomyomas (0/29); 8% of smooth muscle tumor of uncertain malignant potential (1/12); 30% of uterine leiomyosarcomas (6/20); and 4% of extrauterine leiomyosarcomas (1/25).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781491.RALNO2cf7ERCzMn5I_U4aYdETwsZvLCSrTvelr_n5htdE130_provenance.
• NP833451.RAVIH9jPPK3O2tbyuiO-_SYOHqdfyq1qvwEObgaSPsUrE130_assertion description "[MED12 mutations were detected in 54% of classical uterine leiomyomas (15/28) and in 15% of cases in myometrium adjacent to leiomyomas (2/13); 34% of leiomyoma/leiomyomatosis in pelvic/retroperitoneal sites (10/29); 0% of extrauterine leiomyomas (0/29); 8% of smooth muscle tumor of uncertain malignant potential (1/12); 30% of uterine leiomyosarcomas (6/20); and 4% of extrauterine leiomyosarcomas (1/25).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP833451.RAVIH9jPPK3O2tbyuiO-_SYOHqdfyq1qvwEObgaSPsUrE130_provenance.
• NP1125391.RA5bmoP8PNQgzhKXb36FE7KuddV0GdVc1mEXnUoi07T7E130_assertion description "[MED12 mutations were detected in 54% of classical uterine leiomyomas (15/28) and in 15% of cases in myometrium adjacent to leiomyomas (2/13); 34% of leiomyoma/leiomyomatosis in pelvic/retroperitoneal sites (10/29); 0% of extrauterine leiomyomas (0/29); 8% of smooth muscle tumor of uncertain malignant potential (1/12); 30% of uterine leiomyosarcomas (6/20); and 4% of extrauterine leiomyosarcomas (1/25).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1125391.RA5bmoP8PNQgzhKXb36FE7KuddV0GdVc1mEXnUoi07T7E130_provenance.
• NP1125394.RA361weV-ybX8gk8LQMeCxzixCM_QW20AuKrpq_YVJ9K8130_assertion description "[MED12 mutations were detected in 54% of classical uterine leiomyomas (15/28) and in 15% of cases in myometrium adjacent to leiomyomas (2/13); 34% of leiomyoma/leiomyomatosis in pelvic/retroperitoneal sites (10/29); 0% of extrauterine leiomyomas (0/29); 8% of smooth muscle tumor of uncertain malignant potential (1/12); 30% of uterine leiomyosarcomas (6/20); and 4% of extrauterine leiomyosarcomas (1/25).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1125394.RA361weV-ybX8gk8LQMeCxzixCM_QW20AuKrpq_YVJ9K8130_provenance.
• assertion description "[MED12 mutations were detected in 54% of classical uterine leiomyomas (15/28) and in 15% of cases in myometrium adjacent to leiomyomas (2/13); 34% of leiomyoma/leiomyomatosis in pelvic/retroperitoneal sites (10/29); 0% of extrauterine leiomyomas (0/29); 8% of smooth muscle tumor of uncertain malignant potential (1/12); 30% of uterine leiomyosarcomas (6/20); and 4% of extrauterine leiomyosarcomas (1/25).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[MED12 mutations were detected in 54% of classical uterine leiomyomas (15/28) and in 15% of cases in myometrium adjacent to leiomyomas (2/13); 34% of leiomyoma/leiomyomatosis in pelvic/retroperitoneal sites (10/29); 0% of extrauterine leiomyomas (0/29); 8% of smooth muscle tumor of uncertain malignant potential (1/12); 30% of uterine leiomyosarcomas (6/20); and 4% of extrauterine leiomyosarcomas (1/25).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP833543.RAs510Pkjxcq5AS6UIcvgpzOLhH3SrR4takW5xeiDfGqQ130_assertion description "[MED12 mutations were detected in 54% of classical uterine leiomyomas (15/28) and in 15% of cases in myometrium adjacent to leiomyomas (2/13); 34% of leiomyoma/leiomyomatosis in pelvic/retroperitoneal sites (10/29); 0% of extrauterine leiomyomas (0/29); 8% of smooth muscle tumor of uncertain malignant potential (1/12); 30% of uterine leiomyosarcomas (6/20); and 4% of extrauterine leiomyosarcomas (1/25).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP833543.RAs510Pkjxcq5AS6UIcvgpzOLhH3SrR4takW5xeiDfGqQ130_provenance.